NASDAQ:MYND - CNS Response Stock Price, Price Target & More

$2.21 +0.11 (+5.24 %)
(As of 04/23/2018 07:54 AM ET)
Previous Close$2.10
Today's Range$2.03 - $2.27
52-Week Range$1.15 - $7.00
Volume138,800 shs
Average Volume122,922 shs
Market Capitalization$9.65 million
P/E RatioN/A
Dividend YieldN/A
Beta0.32

About CNS Response (NASDAQ:MYND)

MYnd Analytics, Inc. operates as a predictive analytics company primarily in the United States. The company offers objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders. It uses its proprietary neurometric platform, PEER Online, to generate Psychiatric electroencephalogram (EEG) Evaluation Registry (PEER) reports to predict the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders. The company also manages the delivery of telepsychiatry and telebehavioral health services through a network of psychiatrists, psychologists, and therapists. The company was formerly known as CNS Response, Inc. and changed its name to MYnd Analytics, Inc. in November 2015. MYnd Analytics, Inc. was founded in 2000 and is headquartered in Mission Viejo, California.

Receive MYND News and Ratings via Email

Sign-up to receive the latest news and ratings for MYND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:MYND
CUSIPN/A
Phone949-420-4400

Debt

Debt-to-Equity Ratio0.26%
Current Ratio1.63%
Quick Ratio1.63%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$130,000.00
Price / Sales74.12
Cash FlowN/A
Price / CashN/A
Book Value$1.07 per share
Price / Book2.07

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,110,000.00
Net Margins-3,702.19%
Return on Equity-541.96%
Return on Assets-236.61%

Miscellaneous

Employees18
Outstanding Shares4,360,000

How to Become a New Pot Stock Millionaire

CNS Response (NASDAQ:MYND) Frequently Asked Questions

What is CNS Response's stock symbol?

CNS Response trades on the NASDAQ under the ticker symbol "MYND."

How were CNS Response's earnings last quarter?

CNS Response, Inc. (NASDAQ:MYND) issued its earnings results on Monday, August, 14th. The company reported ($0.62) earnings per share for the quarter. The company had revenue of $0.04 million for the quarter. CNS Response had a negative net margin of 3,702.19% and a negative return on equity of 541.96%. View CNS Response's Earnings History.

When is CNS Response's next earnings date?

CNS Response is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for CNS Response.

What price target have analysts set for MYND?

1 brokerages have issued 1-year price targets for CNS Response's shares. Their predictions range from $18.00 to $18.00. On average, they expect CNS Response's share price to reach $18.00 in the next twelve months. View Analyst Ratings for CNS Response.

Who are some of CNS Response's key competitors?

Who are CNS Response's key executives?

CNS Response's management team includes the folowing people:
  • Mr. Donald Eric D'Ambrosio, CFO & Sec. (Age 55)
  • Mr. George C. Carpenter IV, Pres & CEO (Age 59)
  • Dr. Stephen C. Suffin M.D., Co-Founder
  • Mr. Brian MacDonald, Co-Founder and Chief Technology Officer (Age 57)
  • Mr. Michael Tippie, VP of Pharmaceutical Bus. Devel.

Has CNS Response been receiving favorable news coverage?

Media coverage about MYND stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CNS Response earned a news impact score of 0.18 on Accern's scale. They also assigned media stories about the company an impact score of 45.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of CNS Response?

Shares of MYND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CNS Response's stock price today?

One share of MYND stock can currently be purchased for approximately $2.21.

How big of a company is CNS Response?

CNS Response has a market capitalization of $9.65 million and generates $130,000.00 in revenue each year. CNS Response employs 18 workers across the globe.

How can I contact CNS Response?

CNS Response's mailing address is 26522 LA ALAMEDA, MISSION VIEJO CA, 92691. The company can be reached via phone at 949-420-4400 or via email at [email protected]


MarketBeat Community Rating for CNS Response (MYND)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  113
MarketBeat's community ratings are surveys of what our community members think about CNS Response and other stocks. Vote "Outperform" if you believe MYND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYND will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CNS Response (NASDAQ:MYND) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for CNS Response in the last 12 months. Their average twelve-month price target is $18.00, suggesting that the stock has a possible upside of 714.48%. The high price target for MYND is $18.00 and the low price target for MYND is $18.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.002.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.00$18.00$18.00$18.00
Price Target Upside: 714.48% upside637.70% upside429.41% upside393.15% upside

CNS Response (NASDAQ:MYND) Consensus Price Target History

Price Target History for CNS Response (NASDAQ:MYND)

CNS Response (NASDAQ:MYND) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018Maxim GroupDowngradeBuy -> HoldHighView Rating Details
(Data available from 4/23/2016 forward)

Earnings

CNS Response (NASDAQ:MYND) Earnings History and Estimates Chart

Earnings by Quarter for CNS Response (NASDAQ:MYND)

CNS Response (NASDAQ MYND) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018        
8/14/2017Q3 2017($0.62)$0.04 millionViewN/AView Earnings Details
5/15/2017Q2 2017($0.61)$0.03 millionViewN/AView Earnings Details
2/14/2017Q1 2017($0.70)$0.02 millionViewN/AView Earnings Details
8/15/2016Q3 2016($2.00)$0.02 millionViewN/AView Earnings Details
2/17/2016Q1 2016($2.00)$0.03 millionViewN/AView Earnings Details
8/14/2015Q3 2015($2.00)$0.03 millionViewN/AView Earnings Details
5/15/2015Q2 2015($2.00)$0.02 millionViewN/AView Earnings Details
8/14/2014Q3 2014($2.00)$0.03 millionViewN/AView Earnings Details
5/15/2014Q2 2014($2.00)$0.04 millionViewN/AView Earnings Details
8/14/2013Q3 2013($6.00)$0.03 millionViewN/AView Earnings Details
5/15/2013Q2 2013($14.00)$0.03 millionViewN/AView Earnings Details
8/14/2012Q3 2012($15.60)ViewN/AView Earnings Details
5/15/2012Q2 2012($896.00)ViewN/AView Earnings Details
2/14/2012Q1 2012($294.29)ViewN/AView Earnings Details
12/22/2011Q4 2011($510.51)ViewN/AView Earnings Details
8/15/2011Q3 2011($390.39)ViewN/AView Earnings Details
5/16/2011Q2 2011($318.32)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CNS Response (NASDAQ:MYND) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CNS Response (NASDAQ MYND) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 23.39%
Institutional Ownership Percentage: 0.90%
Insider Trading History for CNS Response (NASDAQ:MYND)

CNS Response (NASDAQ MYND) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018John PappajohnDirectorBuy10,000$3.44$34,400.00View SEC Filing  
12/6/2017Peter UnanueDirectorBuy15,000$3.65$54,750.00View SEC Filing  
8/9/2017John PappajohnDirectorBuy5,000$3.34$16,700.00541,290View SEC Filing  
8/2/2017John PappajohnDirectorBuy5,000$3.65$18,250.00536,290View SEC Filing  
7/25/2017John PappajohnDirectorBuy5,000$4.00$20,000.00531,290View SEC Filing  
7/21/2017John PappajohnDirectorBuy10,000$4.25$42,500.00521,290View SEC Filing  
7/18/2017John PappajohnDirectorBuy10,000$4.47$44,700.00511,290View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CNS Response (NASDAQ MYND) News Headlines

Source:
DateHeadline
MYnd Analytics, Adding AI in Telemedicine, Analyst Report and Market OutlookMYnd Analytics, Adding AI in Telemedicine, Analyst Report and Market Outlook
finance.yahoo.com - April 17 at 10:00 AM
MYnd Analytics and Arcadian Telepsychiatry Services Announce Launch of School-Based Telepsychiatry Program Designed to Provide Youths with School-Based  Access to Mental Health ServicesMYnd Analytics and Arcadian Telepsychiatry Services Announce Launch of School-Based Telepsychiatry Program Designed to Provide Youths with School-Based  Access to Mental Health Services
finance.yahoo.com - April 16 at 4:14 PM
What does MYnd Analytics Inc’s (NASDAQ:MYND) Balance Sheet Tell Us About Its Future?What does MYnd Analytics Inc’s (NASDAQ:MYND) Balance Sheet Tell Us About Its Future?
finance.yahoo.com - April 10 at 4:17 PM
Health care-focused Deerfield Management leads Baltimore biotechs $40M roundHealth care-focused Deerfield Management leads Baltimore biotech's $40M round
www.bizjournals.com - March 22 at 4:13 PM
Breakthrough Cancer Technology To Be Funded By The CrowdBreakthrough Cancer Technology To Be Funded By The Crowd
www.bizjournals.com - March 20 at 4:10 PM
MYnd Analytics Inc (NASDAQ:MYND): Should The Recent Earnings Drop Worry You?MYnd Analytics Inc (NASDAQ:MYND): Should The Recent Earnings Drop Worry You?
finance.yahoo.com - March 8 at 5:05 PM
Maxim Group Downgrades MYnd Analytics (MYND) to HoldMaxim Group Downgrades MYnd Analytics (MYND) to Hold
www.americanbankingnews.com - February 13 at 3:10 PM
MYnd Analytics Awarded Canadian Patent on Neuromodulation Platform; Predicts Patients Likely to Respond to TMS for Treating DepressionMYnd Analytics Awarded Canadian Patent on Neuromodulation Platform; Predicts Patients Likely to Respond to TMS for Treating Depression
finance.yahoo.com - February 8 at 9:03 AM
Insider Buying: MYnd Analytics Inc (MYND) Director Acquires 10,000 Shares of StockInsider Buying: MYnd Analytics Inc (MYND) Director Acquires 10,000 Shares of Stock
www.americanbankingnews.com - January 8 at 7:28 PM
MYnd Analytics’ Arcadian Telepsychiatry Services Featured on CBS New YorkMYnd Analytics’ Arcadian Telepsychiatry Services Featured on CBS New York
finance.yahoo.com - January 4 at 5:51 PM
MYnd Analytics (MYND) PT Set at $18.00 by Maxim GroupMYnd Analytics (MYND) PT Set at $18.00 by Maxim Group
www.americanbankingnews.com - January 4 at 3:38 PM
Is It Time To Buy MYnd Analytics Inc (NASDAQ:MYND)?Is It Time To Buy MYnd Analytics Inc (NASDAQ:MYND)?
finance.yahoo.com - January 2 at 7:30 PM
MYND Provides Year-End Business UpdateMYND Provides Year-End Business Update
finance.yahoo.com - January 2 at 8:56 AM
MYnd Analytics Inc. (MYND) Director Buys $54,750.00 in StockMYnd Analytics Inc. (MYND) Director Buys $54,750.00 in Stock
www.americanbankingnews.com - December 6 at 8:52 PM
Maxim Group Analysts Give MYnd Analytics Inc. (MYND) a $18.00 Price TargetMaxim Group Analysts Give MYnd Analytics Inc. (MYND) a $18.00 Price Target
www.americanbankingnews.com - November 26 at 9:32 AM
MYnd Analytics Inc (MYND): How Does It Impact Your Portfolio?MYnd Analytics Inc (MYND): How Does It Impact Your Portfolio?
finance.yahoo.com - November 22 at 6:02 AM
Ignytas entrectinib shows 78% response rate in certain patients with advanced lung cancer; shares ahead 30% premarketIgnyta's entrectinib shows 78% response rate in certain patients with advanced lung cancer; shares ahead 30% premarket
seekingalpha.com - October 19 at 6:37 AM
ZIOPHARM commences early-stage study of gene therapy Ad-RTS-hIL-12 in pediatric brain tumorsZIOPHARM commences early-stage study of gene therapy Ad-RTS-hIL-12 in pediatric brain tumors
seekingalpha.com - October 17 at 1:30 AM
MYnd Analytics to Present at the MicroCap Conference on October 5th in New York City at the Essex HouseMYnd Analytics to Present at the MicroCap Conference on October 5th in New York City at the Essex House
finance.yahoo.com - October 2 at 5:44 PM
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian CancerDelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer
www.bizjournals.com - September 27 at 9:16 AM
CNS Response Inc. (MYND) Stock Rating Reaffirmed by Maxim GroupCNS Response Inc. (MYND) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - September 26 at 6:20 PM
MYnd Analytics Appoints Peter Unanue to Board of DirectorsMYnd Analytics Appoints Peter Unanue to Board of Directors
finance.yahoo.com - September 22 at 10:00 AM
Afraxis Wins NIH Grant to Advance Synaptic Profiling Platform for CNS Drug DiscoveryAfraxis Wins NIH Grant to Advance Synaptic Profiling Platform for CNS Drug Discovery
www.bizjournals.com - September 16 at 6:46 AM
MYnd Analytics Invited to Present at Brain Futures 2017 ConferenceMYnd Analytics Invited to Present at Brain Futures 2017 Conference
finance.yahoo.com - September 8 at 6:08 AM
MYnd Analytics Invited to Present Updated Data at Military Research SymposiumMYnd Analytics Invited to Present Updated Data at Military Research Symposium
finance.yahoo.com - August 30 at 7:02 AM
MYnd Analytics Invited to Present Updated Data at Military Research SymposiumMYnd Analytics Invited to Present Updated Data at Military Research Symposium
finance.yahoo.com - August 30 at 7:02 AM
MYnd Analytics, Inc. :MYND-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017MYnd Analytics, Inc. :MYND-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 8:58 AM
MYnd Analytics, Horizon Healthcare Services, Inc., Hackensack Meridian Health and Cota Inc., Announce Collaboration to Demonstrate Clinical Utility and Cost Savings When Utilizing the Peer Online®MYnd Analytics, Horizon Healthcare Services, Inc., Hackensack Meridian Health and Cota Inc., Announce Collaboration to Demonstrate Clinical Utility and Cost Savings When Utilizing the Peer Online®
finance.yahoo.com - August 17 at 5:40 AM
MYnd Analytics, Inc. Letter to ShareholdersMYnd Analytics, Inc. Letter to Shareholders
finance.yahoo.com - August 16 at 6:25 AM
CNS Response Inc. (MYND) Posts Quarterly  Earnings ResultsCNS Response Inc. (MYND) Posts Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 12:38 PM
CNS Response Inc. (MYND) Director John Pappajohn Purchases 5,000 SharesCNS Response Inc. (MYND) Director John Pappajohn Purchases 5,000 Shares
www.americanbankingnews.com - August 10 at 4:48 PM
MYnd Analytics Adds Experienced Sales & Marketing ExecutiveMYnd Analytics Adds Experienced Sales & Marketing Executive
finance.yahoo.com - August 4 at 3:36 PM
CNS Response Inc. (MYND) Director Purchases $18,250.00 in StockCNS Response Inc. (MYND) Director Purchases $18,250.00 in Stock
www.americanbankingnews.com - August 3 at 9:28 PM
Oxeia Biopharmaceuticals Announces Clinical Advancement Of Concussion TreatmentOxeia Biopharmaceuticals Announces Clinical Advancement Of Concussion Treatment
www.bizjournals.com - August 3 at 6:06 AM
MYnd Analytics Announces Uplisting to NASDAQ and Pricing of $8.79M Underwritten OfferingMYnd Analytics Announces Uplisting to NASDAQ and Pricing of $8.79M Underwritten Offering
finance.yahoo.com - July 31 at 3:09 PM
MYnd Analytics, Inc. :MYND-US: Earnings Analysis: Q2, 2017 By the Numbers : July 17, 2017MYnd Analytics, Inc. :MYND-US: Earnings Analysis: Q2, 2017 By the Numbers : July 17, 2017
finance.yahoo.com - July 31 at 3:09 PM
NASDAQ Listed MYnd Analytics Inc. Announces Closing of $8.79 Million Public OfferingNASDAQ Listed MYnd Analytics Inc. Announces Closing of $8.79 Million Public Offering
finance.yahoo.com - July 31 at 3:09 PM
John Pappajohn Purchases 5,000 Shares of CNS Response Inc. (MYND) StockJohn Pappajohn Purchases 5,000 Shares of CNS Response Inc. (MYND) Stock
www.americanbankingnews.com - July 26 at 10:23 PM
Insider Buying: CNS Response Inc. (MYND) Director Acquires 10,000 Shares of StockInsider Buying: CNS Response Inc. (MYND) Director Acquires 10,000 Shares of Stock
www.americanbankingnews.com - July 25 at 7:51 PM
MYnd Analytics Inc (MYND) Director John Pappajohn Purchases 10,000 SharesMYnd Analytics Inc (MYND) Director John Pappajohn Purchases 10,000 Shares
www.americanbankingnews.com - July 19 at 10:14 PM

SEC Filings

CNS Response (NASDAQ:MYND) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

CNS Response (NASDAQ MYND) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.